Read more

April 13, 2021
7 min watch
Save

VIDEO: Website provides up-to-date data from NASH cirrhosis study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video exclusive, Pol Boudes, MD, chief medical officer of Galectin Therapeutics, spoke about NAVIGATEnash.com, a website for physicians and patients to get information on cirrhosis stemming from nonalcoholic steatohepatitis.

The website data come from NAVIGATE, Galectin’s phase 2b/3 study in NASH cirrhosis.

Boudes said NASH is the leading cause of cirrhosis and currently the only treatment available for NASH cirrhosis is a liver transplant.

He said there are three parts to the website. One part provides education on NASH cirrhosis to patients and their families. The second part gives information to physicians on markers for cirrhosis. The third part is restricted to the study investigators, where they hold discussions on issues occurring with the study.